Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5041126 | 0.82 | NPC1 (0.39) | L3MBTL1MAPTATMLMNAGAA | |
| SCHEMBL3038066 | 0.76 | PARP1 (0.41) | ALDH1A1GPR84 | |
| SCHEMBL9403469 | 0.73 | ALDH1A1 (0.31) | MAPTLMNAALDH1A1 | |
| SCHEMBL3425127 | 0.72 | GPR84 (0.34) | ALDH1A1GPR84 | |
| SCHEMBL9308698 | 0.71 | ALDH1A1 (0.45) | MAPTLMNANPC1RAB9AALDH1A1 | |
| SCHEMBL21298712 | 0.70 | ALDH1A1 (0.40) | L3MBTL1MAPTATMLMNAGAA | |
| SCHEMBL7268595 | 0.69 | ALDH1A1 (0.41) | L3MBTL1MAPTLMNAGAANPC1 | |
| SCHEMBL9206394 | 0.69 | ALDH1A1 (0.61) | MAPTLMNAGAANPC1RAB9A | |
| SCHEMBL9308574 | 0.69 | ALDH1A1 (0.43) | MAPTLMNANPC1RAB9AALDH1A1 | |
| SCHEMBL8823569 | 0.68 | ALDH1A1 (0.40) | MAPTLMNANPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100496490-C | Nitrooxy derivatives of losartan, valsartan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin II receptor blockers for the treatment of cardiovascular diseases | NICOX SA (FR) | 2009-06-10 | — | — | CN | disclosed |
| EP-1653950-B1 | NITROOXY DERIVATIVES OF LOSARTAN, VALSATAN, CANDESARTAN, TELMISARTAN, EPROSARTAN AND OLMESARTAN AS ANGIOTENSIN-II RECEPTOR BLOCKERS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | NICOX SA (FR) | 2008-01-09 | — | — | EP | disclosed |
| US-20060276523-A1 | Nitoroxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-II receptor blockers for the treatment of cardiovascular diseases | NICOX S.A. (FR) | 2006-12-07 | — | — | US | disclosed |
| CN-1832742-A | Nitrooxy derivatives of losartan, valsartan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin II receptor blockers for the treatment of cardiovascular diseases | NICOX SA (FR) | 2006-09-13 | — | — | CN | disclosed |
| EP-1653950-A2 | NITROOXY DERIVATIVES OF LOSARTAN, VALSATAN, CANDESARTAN, TELMISARTAN, EPROSARTAN AND OLMESARTAN AS ANGIOTENSIN-II RECEPTOR BLOCKERS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Nicox S.A. (FR) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005011646-A2 | NITROOXY DERIVATIVES OF LOSARTAN, VALSATAN, CANDESARTAN, TELMISARTAN, EPROSARTAN AND OLMESARTAN AS ANGIOTENSIN-II RECEPTOR BLOCKERS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | NICOX S.A. (FR) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276523-A1 | Nitoroxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-II receptor blockers for the treatment of cardiovascular diseases | AGTR2, AGTR1, REN | L3MBTL1 3622/4885MAPT 2954/4885ATM 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.